In this episode of The Onco’Zine Brief, recorded during CPhI World Wide, held October 24 – 27, 2017 in Frankfurt, Germany, Peter Hofland and Sonia Portillo, interview Charlie Johnson, the CEO of ADC Bio.
ADC Bio, a biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of novel anti-cancer blockbuster drugs known as Antibody-drug Conjugates or ADCs.
Antibody-drug Conjugates are a new class of highly potent biopharmaceutical drugs composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. These novel, targeted agents combine the unique and very sensitive targeting capabilities of antibodies allowing sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.
